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Breast and ovarian cancer are two of the leading causes of cancer deaths among women in the
United States. Overexpression of the HER2/neu oncoprotein has been reported in patients affected
with breast and ovarian cancers, and is associated with poor prognosis. To develop a novel
targeted therapy for HER2/neu expressing tumors, we have constructed a fully human IgE with the
variable regions of the scFv C6MH3-B1 specific for HER2/neu. This antibody was expressed in
murine myeloma cells and was properly assembled and secreted. The Fc region of this antibody
triggers in vitro degranulation of rat basophilic cells expressing human FcεRI (RBL SX-38) in the
presence of murine mammary carcinoma cells that express human HER2/neu (D2F2/E2), but not
the shed (soluble) antigen (ECDHER2) alone. This IgE is also capable of inducing passive
cutaneous anaphylaxis in a human FcεRIα transgenic mouse model, in the presence of a cross-
linking antibody, but not in the presence of soluble ECDHER2. Additionally, IgE enhances antigen
presentation in human dendritic cells and facilitates cross-priming, suggesting that the antibody is
able to stimulate a secondary T-cell antitumor response. Furthermore, we show that this IgE
significantly prolongs survival of human FcεRIα transgenic mice bearing D2F2/E2 tumors. We
also report that the anti-HER2/neu IgE is well tolerated in a preliminary study conducted in
Macaca fascicularis (cynomolgus) monkeys. In summary, our results suggest that this IgE should
be further explored as a potential therapeutic against HER2/ neu overexpressing tumors, such as
breast and ovarian cancers.
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Introduction
Breast cancer is one of the leading causes of cancer deaths, second only to lung cancer,
among women in the United States [1]. Ovarian cancer is the leading cause of death from all
gynecological malignancies and is the fifth overall cause of cancer deaths among women in
the United States [1]. Additionally, advanced disease remains generally incurable for both
malignancies, and the 5-year survival rate for these patients ranges from 23 to 28% [1].
Approximately 25% of breast cancers demonstrate amplification of the oncogene HER2/neu,
which is associated with more aggressive disease and poor prognosis [2, 3]. Overexpression
of HER2/neu has also been described in 9–32% (depending on the study) ovarian cancer
tissue [3, 4]. As is the case for breast cancer, HER2/neu overexpression in ovarian cancer is
associated with poor prognosis [5, 6]. HER2/neu is a member of the epidermal growth factor
receptor (EGFR) family that have intrinsic tyrosine kinase activity that leads to the
activation of downstream signaling pathways of cell proliferation and survival [7].
The humanized monoclonal IgG1 antibody trastuzumab (Herceptin®) that binds to the
extracellular domain of HER2/neu was initially approved in 1998 by the Food and Drug
Administration for the treatment of HER2/neu overexpressing advanced breast cancer. Since
then trastuzumab has shown efficacy against breast cancer both as an adjuvant therapy and
as a treatment of metastatic disease (reviewed in [8]). However, the majority of patients with
advanced breast cancer that are treated with trastuzumab alone or combined with
chemotherapeutic agents eventually relapse and the median time to progression is less than 1
year [8, 9]. Additionally, a significant number of breast cancer patients do not respond to
trastuzumab-based therapies despite the high level of HER2/neu expression [8–10].
Furthermore, in a Phase II clinical trial in patients with HER2/neu overexpressing recurrent
or refractory ovarian or primary peritoneal carcinoma that were treated with trastuzumab
alone, a low rate of objective response (7.3%) was observed [11]. While trastuzumab has
shown efficacy in a subset of patients with either breast or ovarian cancer, additional
strategies to target HER2/neu overexpressing tumors are still needed.
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Like trastuzumab, the majority of antibody therapies for the treatment of cancer utilize
antibodies that are of the IgG class. However, antibodies of the IgE class may also be
potential cancer therapeutics since they have several potential advantages over their IgG
counterparts. IgE mediates allergic reactions, which is due to the presence of effector cells in
the tissue that are sensitized by IgE bound to Fc epsilon receptor I (FcεRI). These effector
cells are degranulated after crosslinking of the IgE that is triggered by a multi-epitope
antigen interaction. IgE can also mediate antigen presentation via the interaction with FcεRs
expressed on antigen-presenting cells (APC) such as dendritic cells (DC) [12–14]. IgE has
been suggested to provide protection against parasitic infections [15], although this function
is controversial [16, 17]. Research on cancer and IgE belongs to the new field of
“AllergoOncology” [12]. This field has two aims: (1) to reveal the function of IgE-mediated
immune responses against cancer cells in order to elucidate the understanding of its biology
and (2) to develop novel IgE-based treatment options against malignant diseases [18]. A key
advantage associated with IgE is its exceptionally high affinity for the FcεRs. There are two
FcεRs, the FcεRI which binds IgE with high affinity (Ka = 1010 M−1) and is expressed on
human monocytes, macrophages, eosinophils, basophils, mast cells, Langerhans cells, and
DC, and the FcεRII (CD23) which binds IgE with lower affinity (Ka = 108 M−1) and is
expressed on human eosinophils, monocytes, macrophages, and DC [12– 14, 19]. Thus, the
affinity of IgE for FcεRI is at least two orders of magnitude higher than that of IgG for the
FcγRs (FcγRI-III) and in the case of FcεRII is as high as that of IgG for its high-affinity
receptor FcγRI (CD64). Another advantage of the IgE molecule is the low endogenous
serum concentration in humans, which is only 0.02% of total circulating immunoglobulins,
whereas IgG is the most abundant at 85% [20]. Thus, the competition for FcR occupancy is
much lower for IgE. Another potential advantage is that there is no known inhibitory FcεR
as there is for FcγR. In order to develop a new therapy for HER2/neu expressing
malignancies, we now describe the development and characterization of a novel fully human
anti-HER2/neu IgE and evaluate its potential as a cancer therapeutic.
Materials and methods
Cell lines
The human breast cancer cell line SK-BR-3 was obtained from ATCC (American Type
Culture Collection, Manassas, VA) and cultured in RPMI 1640 (Invitrogen Corporation,
Carlsbad, CA). D2F2/E2 murine mammary cells that express human HER2/neu and the
parental cell line D2F2 (syngeneic to BALB/c mice) were kind gifts from Dr. Wei-Zen Wei
(Wayne State University, Detroit, MI) [21] and were grown in IMDM medium (Invitrogen
Corporation). The Chinese Hamster Ovary cell line (CHO 3D10) expressing the human
FcεRIα subunit [22] and the RBL SX-38 rat basophil leukemic cell line expressing the full
human receptor (FcεRI) [23] were kindly provided by Dr. Jean-Pierre Kinet (Beth Israel
Deaconess Medical Center, Boston, MA) and grown in IMDM. Both RPMI and IMDM
media for all cell lines were supplemented with 100 U/ml penicillin, 10 µg/ml streptomycin,
and 10% (v/v) heat-inactivated fetal bovine serum (Atlanta Biologicals, Atlanta, GA).
Growth medium for D2F2/E2 and RBL SX-38 cells was additionally supplemented with 1
mg/ml G418 (Invitrogen Corporation).
Production of recombinant antibodies
The fully human anti-HER2/neu IgE was constructed using the DNA encoding the variable
regions of the single-chain Fv (scFv) C6MH3-B1 that was isolated from a human phage
library and affinity matured in vitro by sequential mutation of the third complimentary
determining region (CDR3) in both the variable heavy chain (VH) and the variable light
chain (VL) regions [24, 25]. The affinity-matured VL and VH regions were cloned into either
the human κ light chain or the human ε heavy chain (the classic secreted isoform)
Daniels et al. Page 3
Cancer Immunol Immunother. Author manuscript; available in PMC 2013 July 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
expression vectors, respectively, both of which were obtained as kind gifts from Dr. Sherrie
L. Morrison (UCLA, Los Angeles, CA) [26]. The antibody was expressed in the murine
myeloma cell line P3×63Ag8.653 and the transfectomas were grown in rollerbottles for
antibody production as previously described [27]. The IgE was then purified from cell
culture supernatants on an immunoaffinity column prepared by coupling an anti-human IgE
(omalizumab, Xolair® , Genentech, Inc. San Fransisco, CA, USA) to cyanogen bromide-
activated Sepharose (GE Healthcare, Piscataway, NJ), as recommended by the
manufacturer. A non-HER2/neu-specific IgE (NS IgE) with human constant regions was
produced in the same manner alongside the anti-HER2/neu IgE and was used as a negative
control. The anti-HER2/neu IgG3 that contains the C6MH3-B1 scFv variable regions has
been previously described [28]. Rituximab (anti-CD20 IgG1; NS IgG) and trastuzumab
(anti-HER2/neu IgG1) were obtained from Genentech. The extracellular domain of HER2/
neu (ECDHER2 ) was produced as previously described [29]. All proteins were quantified
using the BCA Protein Assay (ThermoFisher Scientific, Walnut, CA).
Flow cytometry (binding analysis)
Cells were detached from tissue culture dishes using 0.5 mM EDTA and incubated with 1 µg
of the various antibodies for 2 h on ice. Cells were then washed in buffer (2 mM EDTA,
0.5% BSA in PBS) and binding was detected using an anti-human κ fluorescein
isothiocyanate (FITC)-conjugated secondary antibody (BD Biosciences, San Jose, CA).
Cells were also stained with an anti-FcεRI phycoerythrin (PE)-conjugate (eBioscience, San
Diego, CA) to ensure expression of the receptor on the surface of the cells. All cells were
washed, fixed with 2% paraformaldehyde in PBS, and analyzed on a Becton–Dickinson
FACScan Analytic Flow Cytometer in the UCLA Jonsson Comprehensive Cancer Center
and Center for AIDS Research Flow Cytometry Core Facility. Histograms were created
using the FCS Express V3 software.
In vitro degranulation assay
RBL SX-38 cells were seeded in a 48-well plate at a density of 105 cells/well. After
adherence to the plates, these cells were sensitized with 1 µg of the anti-HER2/neu IgE, anti-
HER2/neu IgG3, or the NS IgE for 2 h. Sensitized RBL SX-38 cells were then incubated for
an additional 2 h with either buffer alone, D2F2/E2 (50,000 cells), D2F2 (50,000 cells), or
soluble ECDHER2 (1 or 5 µg). Cell supernatants (50 µl) were transferred to a fresh 96-well
plate, and the amount of β-hexosaminidase released into the medium was determined using
100 µl of 2.5 mM p-nitrophenyl-N-acetyl-β-D-glucosamine (Sigma Aldrich, St. Louis, MO)
in 50 mM citrate buffer (50 mM citric acid, 50 mM tribasic sodium citrate, pH 4.5).
Reactions were quenched by the addition of 100 µl sodium carbonate buffer (50 mM sodium
carbonate, 50 mM sodium bicarbonate, pH 10). Absorbance at 405 nm was determined
using a DTX880 Multimode detector (Beckman Coulter, Fullerton, CA). β-hexosaminidase
release in experimental samples is expressed as a percent of total content within the
basophils as determined by separate treatment with 1% Triton X-100 in PBS. The percent
degranulation was determined by the following equation [(experimental release–
spontaneous release)/(maximum release–spontaneous release)] × 100.
In vivo passive cutaneous anaphylaxis assay
Since human IgE does not interact with murine FcεRI [14], BALB/c human FcεRIα
transgenic mice (a kind gift from Dr. Jean-Pierre Kinet, Beth Israel Deaconess Medical
Center, Boston, MA) were used for this assay [30]. In this transgenic mouse model, the
murine FcεRIα is knocked out and replaced by its human couterpart. The human FcεRIα
associates with the murine FcεRIλ and FcεRIβ chains resulting in a chimeric FcεRI that can
be activated by human IgE [30–32]. The expression of the human FcεRIα in these animals
mimics the expression pattern found in humans. It is important to note that these animals are
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not transgenic for human CD23 and thus, only express murine CD23 (which does not bind
human IgE [33]). The assay was performed as previously described [34]. Specifically, the
animals were intradermically injected with 1 µg of antibody or buffer (PBS) control. After a
4-h incubation, the mice were injected intravenously (i.v.) with 25 µg of anti-human j
antibody (used to artificially cross-link the human IgE) or 2 µg ECDHER2 in 1% Evan’s Blue
tetra-sodium salt (Tocris Bioscience, Ellisville, MO) in PBS. After 10 min, mice were
euthanized and the skin removed. Leakage of the blue dye into the skin due to a local IgE-
induced inflammatory response was assessed using the NIH ImageJ software. Color
intensity is reported as the mean signal per pixel.
Antigen presentation assay
Human monocytes were isolated from peripheral blood mononuclear cells (PBMC) using
the EasySep Human Monocyte Enrichment Negative Selection Kit (StemCell Technologies,
British Columbia, Canada). Monocytes were cultured for 7 days in 4 ng/ml IL-4 and 0.1 ng/
ml GM-CSF to differentiate them to DC, which are then loaded with 1.25 or 2.5 µg/ml
ECDHER2 complexed to equimolar amounts of either a NS IgG1 (2.5 µg/ml), anti-HER2/neu
IgE (2.0 µg/ml), or anti-HER2/neu IgG1 (2.5 µg/ml). After loading for 4 h, the DC were
matured with 0.18 ng/ml IFN-α and 10 ng/ml TNF-α. Autologous T cells are added on day
8. Cells were incubated for 7 days and restimulated with freshly pulsed DC. The cells were
stimulated for a total of three rounds. During the last stimulation round, cells were treated
with Brefeldin A to block cytokine secretion, and T cells were harvested and analyzed for
activation of CD4 (CD3+/CD8−) and CD8 (CD3+/CD8+) IFN-γ producing T cells by
intracellular cytokine staining and flow cytometry.
Anti-tumor activity in FcεRIa transgenic mice
Female BALB/c human FcεRIα transgenic mice 6–12 weeks old were challenged
intraperitoneally (i.p.) with 2 × 105 D2F2/E2 cells. Two days after tumor challenge, age-
matched mice were treated i.p. with 100 µg of the anti-HER2neu IgE or Hank’s Balanced
Salt Solution (HBSS) alone (5–6 animals per group per experiment). Mice were treated i.p.
for a second time on day 4 with 100 µg of the same treatments and survival was recorded.
Kaplan–Meier plots were generated using GraphPad Prism 4. Statistical analysis was
performed using this software and the Log Rank Test.
Pilot study in M. fascicularis (cynomolgus) monkeys
This study was conducted at WuXi AppTec (XiShan Site, Suzhou, Jiangsu Province, China)
under the approval of that facility’s IACUC. Two male monkeys with a body weight of 4.74
and 6.57 kg were used in the study. One animal received a low-dose i.v. infusion of 0.0024
mg/kg of the anti-HER2/neu IgE (10 ml over 20 min of infusion) and the other animal
received 0.08 mg/kg, (10 ml over 20 min). Blood was collected from the animals at pre-
dose, 30 min, and 1 week post-dose. Serum concentration of anti-HER2/neu IgE was
determined using ELISA (Immunology Consultants Laboratory, Inc., Newberg, OR).
Animals were monitored closely by a veterinarian for signs of distress for 1 h following the
infusion and monitored for change in food consumption and general health for one
additional week following dosing.
Results
Binding to antigen and FcεRI
The fully human anti-HER2/neu IgE, expressed in murine myeloma cells, was properly
assembled and secreted and showed the expected molecular weight (190 kDa) as verified
using SDS-PAGE analysis (Fig. 1a). Binding of both the anti-HER2/neu IgG3 and anti-
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HER2/neu IgE to the surface of the human breast cancer cell line SK-BR-3 was detected by
flow cytometry (Fig. 1b). Binding of both antibodies was also detected at similar levels on
the surface of D2F2/E2 murine mammary carcinoma cells that express human HER2/neu
(Fig. 1b). Importantly, binding to cell surface HER/neu could be blocked by the addition of
soluble antigen (ECDHER2; Fig. 1c). Thus, the anti-HER2/neu IgE is able to bind the soluble
antigen in solution as well as cell surface antigen. Since binding of IgE to FcεRI occurs
through the α subunit, we used CHO cells that express the human FcεRIα subunit on the
cell surface (CHO-3D10 cells) to detect this interaction. Both the anti-HER2/neu IgE and
the NS IgE bound to the surface of CHO-3D10 cells (Fig. 2) as expected since they contain
the same Fc region. These studies confirm that the fully human IgE is able to bind antigen
(both soluble as well as cell-surface bound) and the FcεRI.
IgE-mediated in vitro degranulation
When FcεRI is crosslinked due to the binding of antigens (most commonly known as
allergens) to multiple IgE on the surface of an effector cell (either mast cells or basophils),
these cells rapidly degranulate, releasing a variety of factors that trigger the acute IgE-
mediated type I immediate hypersensitivity (anaphylactic-type) response [15]. We explored
the capability of the anti-HER2/neu IgE to induce degranulation of such effector cells in
vitro. For this assay, RBL SX-38 rat basophil leukemic cells expressing the entire human
FcεRI α, β, and γ subunits) were used [23]. These cells are also appropriate to use in this
assay since they are a natural effector cell for this type of reaction. β-hexosaminidase is an
enzyme that is contained within the secretory granules of basophils and mast cells and was
used to measure degranulation, as reported previously [23, 35]. Allergens are multi-epitopic
and induce crosslinking and degranulation of sensitized effector cells. Our IgE is not
expected to induce cross-linking of the FcεRI when complexed with soluble antigen,
consistent with the interaction of ECDHER2 with the anti-HER2/neu IgE, which is expected
to be mono-epitopic in nature, as well as the fact that ECDHER2 does not form homodimers
in solution [36]. Our data show that degranulation of RBL SX-38 cells was only observed in
the presence of D2F2/E2 cells, which contain multiple copies of the receptor on the cell
surface, and not with the D2F2 parental cell line that lacks expression of the antigen (Fig.
3a). Additionally, degranulation was not observed in the presence of the IgE and soluble
ECDHER2 (Fig. 3b). These studies were conducted under established conditions in which
IgE bound to a multi-epitopic antigen results in extensive basophilic degranulation. Taken
together, these studies show that the anti-HER2/neu IgE is functional in vitro.
In vivo passive cutaneous anaphylaxis assay
Since human IgE does not interact with murine FcεRI [14], the ability of the anti-HER2/neu
IgE to induce a local hypersensitivity type I (anaphylactic) response in vivo was evaluated
using human FcεRIα transgenic animals. Sensitization of effector cells in the skin of these
animals with anti-HER2/neu IgE lead to a local hypersensitivity reaction after artificial
cross-linking by systemic injection of an anti-human κ antibody (Fig. 4a). This IgE-
mediated inflammatory reaction is evidenced by the leakage of the Evan’s blue dye into the
skin due to vasodilation. This reaction was not observed when ECDHER2 was injected
systemically (Fig. 4b), which is consistent with our in vitro data. Leakage of the dye into the
skin was quantified and is shown in Fig. 4c. Taken together, these studies indicate that the
anti-HER2/neu IgE is capable of inducing a local anaphylactic reaction when adequately
crosslinked and further suggest that soluble ECDHER2 will not induce a hypersensitivity
reaction.
IgE enhanced in vitro antigen presentation
In humans, in addition to mast cells and basophils, FcεRI is expressed on monocytes,
macrophages, and DC [13, 14]. DC are the most potent APC and can process antigens via
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cross-presentation, allowing the induction of a cell-mediated immune response [37, 38].
Human DC express both FcεRI and FcεRII (CD23) [14, 19] and are capable of interacting
with human IgE bound to antigen. IgE-facilitated antigen presentation can occur through
binding of human IgE to either CD23 [39] or FcεRI [40]. It has been shown that processing
and presentation of the antigen is required for T-cell activation [39]. The ability of cultured
human DC isolated from human healthy donors to induce T-cell activation was studied in
vitro. Human DC stimulated with the ECDHER2 complexed to the anti-HER2/neu IgG1
slightly increased the activation of IFN-γ producing autologous T cells (Fig. 5). Complexes
consisting of ECDHER2 and anti-HER2/neu IgE increased T-cell activation, both for CD4
and CD8 cells (Fig. 5). The activation and expansion of CD8 cells is indicative of cross
presentation. These data show that the anti-HER2/neu IgE enhances antigen presentation in
vitro and suggest that the antibody is capable of stimulating a secondary T-cell-mediated
response that would enhance the in vivo antitumor immune response.
Anti-tumor activity in FcεRIα transgenic mice
Transgenic mice expressing human FcεRIα were used to study the in vivo anti-cancer
activity of the anti-HER2/neu IgE. Two treatments of 100 µg anti-HER2/neu IgE on days 2
and 4 after tumor challenge significantly prolonged the survival (P <0.001) of mice bearing
D2F2/E2 murine mammary carcinoma cells (syngeneic to BALB/c) expressing human
HER2/neu compared with buffer alone (Fig. 6). The median survival time was increased
from 28 to 39 days. This included 5 long-term survivors that survived beyond 98 days.
Pilot study in cynomolgus monkeys
Cynomolgus monkeys (M. fascicularis) were chosen to evaluate the overall safety of the
anti-HER/neu IgE since human IgE has been shown to mediate anaphylaxis in these animals
[41]. Additionally, due to the high sequence homology (about 99%) between human and
cynomolgus ECDHER2, this species has been used previously for studies on other HER2/
neu-targeted antibodies, including trastuzumab [42–44]. Two doses were chosen for this
initial study: a low dose (0.0024 mg/kg) and a high dose (0.08 mg/kg). Serum from the two
animals was collected before dosing, as well as 30 min and 1 week after dosing. Serum
concentrations 30 min after dosing showed the presence of circulating human anti-HER2/
neu IgE (Fig. 7). One week later, no human IgE was detected in the serum of the animals.
This decrease is not surprising due to the serum half-life of IgE (2 days), which is short
compared with IgG (21 days) [45]. No changes in eating habits or general health were
observed for 1 week after dosing. This preliminary study shows that the anti-HER2/neu IgE
can be safely infused into cynomolgus monkeys and that the antibody redistributes out of the
circulation, presumably to the tissues where it is bound to the FcεRs or HER2/neu.
Discussion
Most therapeutic antibodies used in the clinic for cancer therapy are of the IgG isotype [46].
However, antibodies of the IgE isotype also have the potential to be particularly useful for
this purpose. Evaluation of the anti-cancer efficacy of IgE molecules was pioneered by Nagy
et al. [47] who developed a murine monoclonal IgE specific for the major envelope
glycoprotein (gp36) of mouse mammary tumor virus (MMTV) and demonstrated its in vivo
efficacy. Since then, other anti-cancer IgE molecules have been developed. Kershaw et al.
[48] developed a murine monoclonal IgE (30.6) specific for an antigenic determinant
expressed on colorectal adenocarcinoma cells. Mouse IgE 30.6 transiently inhibited the
growth of established human colorectal carcinoma COLO 205 cells growing subcutaneously
in severe combined immune deficient (SCID) mice. By contrast, a mouse IgG 30.6 and a
mouse/ human chimeric IgE 30.6 did not show anti-tumor effect. The lack of effect
exhibited by the mouse/human chimeric IgE 30.6 is expected since mouse FcεRI does not
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bind human IgE [14, 31, 32]. Gould et al. [49–51] developed a mouse/human chimeric IgE
(MOv18-IgE) and IgG MOv18 (IgG1) specific for the ovarian cancer antigen folate binding
protein. In a SCID mouse xenograft model of human ovarian carcinoma, mice were
reconstituted with human PBMC to provide effector cells capable of binding human IgE.
The beneficial effects of MOv18-IgE were greater and of longer duration than those of
MOv18-IgG1. More recently, a humanized anti-HER2/neu IgE with the variable regions of
trastuzumab (Herceptin®) was developed and produced transiently in human embryonic
kidney (HEK293) cells. This IgE was capable of triggering basophilic cell degranulation and
antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro in the presence of human
HER2/neu expressing cells [35].
We now report the development of a new fully human anti-HER2/neu IgE, expressed in
murine myeloma cells, that does not compete with trastuzumab for binding to HER2/neu
[52]. A murine myeloma cell-based expression system was used since it is a reliable and
permanent source of antibody. Additionally, several FDA-approved therapeutic antibodies
have been expressed using murine myeloma cells [53]. Obviously, this does not preclude the
use of other expression systems in the future if deemed necessary. We have found that this
IgE binds antigen, binds effector cells, and that the Fc region is active since it can induce
degranulation of FcεRI bearing cells both in vitro and in vivo. This suggests that the IgE is
capable of mediating other Fc effector functions such as ADCC and ADCP (antibody-
dependent cell-mediated phagocytosis) as has been described for other IgE [35, 54]. Mast
cells often infiltrate tumors and in some cases support angiogenesis and tumor growth [55].
However, it has also been shown that mast cells can modulate regulatory T cell and DC
function leading to a potent T-cell-mediated immune response [56, 57]. Our data suggests
that in the tumor microenvironment, the anti-HER2/neu IgE may induce an acute
inflammatory response leading to an anti-tumor effect. Even binding of the IgE to dead cells
or their fragments in the tumor microenvironment may contribute to such an acute
inflammatory response, which through the bystander effect may damage live tumor cells and
their supportive stromal cells. Further studies are needed to fully examine the effect of the
IgE and FcεR-bearing cells including mast cells in the complex tumor microenvironment.
A major concern of the systemic use of an IgE molecule that targets a self-protein for
therapeutic purposes is the possible induction of a systemic hypersensitivity (anaphylactic)
reaction. This is a particular concern since patients with breast and ovarian cancer that
overexpress HER2/neu often have elevated levels of circulating ECDHER2 in the blood [58–
61]. However, consistent with a mono-epitopic interaction with the antigen, we did not
observe in vitro or in vivo degranulation in the presence of ECDHER2. A serum
concentration of ECDHER2 above 15 ng/ml is considered to be elevated in cancer patients,
with highly elevated levels being above 100 ng/ml [58, 62]. The average concentration in
the serum of patients with advanced disease is 35–40 ng/ ml [58, 59]. Even at the high
concentration of ECDHER2 (which is equivalent to 1–2 µg/ml based on the blood volume of
a mouse) used in our in vivo studies, soluble ECDHER2 did not induce a local
hypersensitivity reaction. Additionally, we have also observed in preliminary studies that
systemic injection of complexes of ECDHER2 and anti-HER2/neu IgE (with fourfold molar
excess of ECDHER2) or systemic injection of 100 µg of the anti-HER2/neu IgE followed 4 h
later by systemic injection of 38 µg of ECDHER2 did not induce systemic anaphylactic shock
and were well tolerated in human FcεRIα transgenic mice. Furthermore, no systemic
reactions or other unexpected adverse events were evident in cynomolgus monkeys injected
with up to 0.08 mg/kg of the anti-HER2/neu IgE despite the fact that HER2/neu is expressed
in many normal tissues and a basal level of ECDHER2 can be found in the blood of healthy
individuals [7, 63]. Although we used relatively low doses for the monkey study, they were
based on previous studies in humans using different immune stimulating therapeutic
antibodies [64–66]. Additionally, it is the first study carried out in this animal model, and it
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serves as a starting point for further toxicity, pharmacokinetic, and biodistribution studies.
Our data suggest that a systemic anaphylactic reaction may not be induced by circulating
soluble antigen, even in cancer patients with high serum levels of ECDHER2. We have
demonstrated for the first time that systemic infusion of IgE targeting a tumor-associated
antigen is feasible in non-human primates. Although additional cautious studies are required,
our initial results suggest that the anti-HER2/neu IgE has a potential manageable safety
profile allowing the antibody to mobilize novel immune effector mechanisms to fight
cancer.
IgE, through the interaction with FcεRI, has been shown to act as an adjuvant in a tumor
vaccination setting [67]. This study showed that vaccination with IgE-coated tumor cells
protected animals against subsequent tumor challenge. ECDHER2 alone is known to be
poorly immunogenic in patients [68]. Our results show that the anti-HER2/neu IgE, when
complexed with soluble ECDHER2, stimulates more IFN-γ production than IgG complexed
with that antigen. This suggests that it is more effective in antigen presentation (and the
subsequent activation of T cells) when compared with the IgG molecule under these
conditions. However, further studies are needed to confirm these results. Thus, our studies
support the adjuvant effect of IgE and suggest that the interaction of anti-HER2/neu IgE
with circulating ECDHER2 in cancer patients may elicit an anti-HER2/neu T-cell response
through increased antigen presentation and ultimately anti-cancer immunity. It is also
expected that binding of the IgE to HER2/neu on cancer cells, apoptotic cells, and even
membrane fragments resulting from tumor cell lysis can facilitate their uptake by APC,
thereby enhancing antigen presentation and the secondary immune response. It has been
previously shown that IgE complexed with a mono-epitopic antigen through its interaction
with CD23/FcεRII is capable of mediating antigen presentation in the absence of receptor
cross-linking [69]. Additionally, both mast cells [70] and basophils [71] have been shown to
act as APC of antigen bound to IgE. Further studies are needed to determine the potential
involvement of APC and their FcεRs in the anti-cancer effect of our anti-HER2/neu IgE.
In the current study, an in vivo anti-cancer effect was observed in a syngeneic model of
intraperitoneal tumors in human FcεRIα transgenic mice. Breast cancer patients may
present with peritoneal carcinomatosis as part of the metastasis process [72, 73]. Most
ovarian cancers are epithelial tumors that can slough off the ovary and enter the peritoneal
cavity [74]. We observed significant protection in the peritoneal cancer model, suggesting
that the anti-HER2/neu IgE may be potentially useful for the treatment of peritoneal cancers.
Since our IgE showed no direct in vitro cytotoxicity against D2F2/E2 cells (Daniels et al.,
unpublished data), our data suggest that the anti-cancer effect observed in vivo is due to
antibody Fc effector functions. It is important to note that the animals are only transgenic for
human FcεRIα. Since human IgE does not interact with mouse CD23/FcεRII [33], the role
of this receptor in the anti-tumor effects mediated by the anti-HER2/neu IgE could not be
evaluated. Thus, the overall effects of the IgE may be underestimated. However, additional
studies are needed to understand the mechanism of the observed in vivo anti-cancer activity
and to compare this efficacy with that of anti-HER/neu IgG.
In summary, our studies describe a totally human anti-HER2/neu IgE molecule that
demonstrates in vitro activity and anti-tumor protection in mice, while being well tolerated
in animal models. Although further evaluation of the anti-cancer effect and safety profile of
this molecule is warranted, our results suggest the potential use of this novel molecule as a
therapy of HER2/neu overexpressing cancers, such as breast and ovarian cancer.
Importantly, this IgE can potentially be used in combination treatment strategies with
various other anti-cancer agents in order to achieve a maximal therapeutic effect.
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Fig. 1.
Binding to HER2/neu on the surface of cancer cells. a SDS–PAGE analysis of the anti-
HER2/neu IgE under both reducing and non-reducing conditions as compared to the anti-
HER2/neu IgG3. b SK-BR-3 (top panel) and D2F2/E2 (bottom panel) cells were incubated
with 1 µg of a nonspecific (NS) IgG1, anti-HER2/ neu IgG3, anti-HER2/neu IgE, or a NS
IgE. Binding was detected using an anti-human κ-FITC antibody. Samples were analyzed by
flow cytometry. Each histogram shows cells incubated with labelled secondary antibody
alone (gray) and experimental antibody (black). Data are representative of three independent
experiments. c D2F2/E2 cells were incubated with 0.1 µg of the anti-HER2/neu IgG3, anti-
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HER2/neu IgE, or a NS IgE with or without tenfold excess (1 µg) soluble ECDHER2.
Binding was detected using an anti-human κ-FITC antibody. Samples were analyzed by
flow cytometry. Data are representative of three independent experiments
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Fig. 2.
Binding to the human FcεRIα subunit. CHO-3D10 or the parental CHO (not expressing
human FcεRIα) cells were treated with 1 µg of anti-HER2/neu IgG1 (trastuzumab), NS IgE,
or anti-HER2/neu IgE. Binding was detected with an anti-human κ-FITC antibody. Cells
were also incubated with an anti-FcεRIα PE-conjugated antibody to verify receptor surface
expression. All samples were analyzed by flow cytometry. Each histogram shows cells
incubated with labelled secondary antibody alone (gray) and experimental antibody (black).
Data are representative of three independent experiments
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Fig. 3.
IgE-mediated in vitro degranulation. RBL SX-38 cells were sensitized by a 2-h incubation
with either anti-HER2/neu IgE, anti-HER2/neu IgG3, or the NS IgE. The release of β-
hexosaminidase into cell supernatants was monitored in the presence of a D2F2/E2 (HER2/
neu+ cells), D2F2 (HER2/neu− cells), or buffer alone, or b D2F2/E2 cells, soluble ECDHER2,
or buffer alone. Data are representative of three separate experiments. Error bars represent
SD *P < 0.05 (Student’s t test) compared with either component alone
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Fig. 4.
IgE-mediated passive cutaneous anaphylaxis in human FcεRIα transgenic animals. Images
of the skin of from mice injected intradermically with PBS or 1 µganti-HER2/neu IgE in a
volume of 50 µl. Panels 1, 2, and 3 show images from three different animals per treatment.
After 4 h, a 25 µg of anti-human kappa (hκ) or b 2 µg ECDHER2 was injected in 1% Evan’s
Blue in PBS. The mice were euthanized after 10 min. c Leakage of the blue dye into the skin
due to a local IgE-induced inflammatory response was assessed using the NIH ImageJ
Software (graph corresponds to the images shown). The color intensity is reported as the
mean signal per pixel and is the average of three different animals corresponding to the
images shown in (A) and (B). *P <0.01 Student’s t test
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Fig. 5.
IgE enhanced antigen presentation and activation of CD8+ and CD4+ T cells. In vitro T-cell
activation by human monocyte-derived DC. CD4+ and CD8+ T-cell responses generated by
DC armed with ECDHER2 alone or combined with anti-HER2/neu IgG1, anti-HER2/neu
IgE, or a NS IgG1. After three rounds of weekly stimulation, responses were measured as
numbers of CD4+ and CD8+ T cells producing intracellular IFN-γ. Activated CD8 cells
(CD8+/IFN-γ+) are shown in the upper right quadrants and activated CD4 cells (CD8−/IFN-
γ+) are shown in the upper left quadrants. Data are representative of two independent
experiments
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Fig. 6.
In vivo anti-cancer activity in human FcεRIα transgenic mice. Survival plot showing
survival of animals challenged i.p. with D2F2/E2 mammary carcinoma cells expressing
human HER2/neu on day 0. Animals were treated i.p. with 100 µg anti-HER2/neu IgE on
day 2 and again on day 4. Data shown are the combined results from three independent
experiments
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Fig. 7.
Pilot study in M. fascicularis (cynomolgus) monkeys. Single intravenous infusion of the
anti-HER2/neu IgE at 0.0024 mg/kg and at 0.08 mg/kg over 20 min. Anti-HER2/neu IgE
serum levels predose, 30-min post-infusion, and at 1 week post infusion are shown. LLQ
lowest limit of quantification
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